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Epilepsy is a chronic brain disorder that affects 1% of the human population worldwide.
Immune responses are implicated in seizure induction and the development of epilepsy.
Pre-clinical and clinical evidence have accumulated to suggest a positive feedback cycle
between brain inﬂammation and epileptogenesis. Prolonged or recurrent seizures and
brain injuries lead to upregulation of proinﬂammatory cytokines and activated immune
responses to further increase seizure susceptibility, promote neuronal excitability, and
induce blood–brain barrier breakdown. This review focuses on the potential role of
innate and adaptive immune responses in the pathogenesis of epilepsy. Both human
studies and animal models that help delineate the contributions of brain inﬂammation in
epileptogenesis will be discussed. We highlight the critical role of brain-resident immune
mediators and emphasize the contribution of brain-inﬁltrating peripheral leukocytes.
Additionally, we propose possible immune mechanisms that underlie epileptogenesis.
Several proinﬂammatory pathways are discussed, including the interleukin-1 receptor/toll-
like receptor signaling cascade, the pathways activated by damage-associated molecular
patterns, and the cyclooxygenase-2/prostaglandin pathway. Finally, development of better
therapies that target the key constituents and processes identiﬁed in these mechanisms
are considered, for instance, engineering antagonizing agents that effectively block these
pathways in an antigen-speciﬁc manner.
Keywords: seizure, epilepsy, epileptogenesis, immune response, inflammation, microglia, astrocytes,
T lymphocytes
INTRODUCTION
Epilepsy is a chronic neurological condition characterized by
recurring seizures, and is often accompanied by cognitive deﬁcits
and mood disorder (Devinsky, 2004; Pellock, 2004; Jones et al.,
2008). It affects approximately 1% of the world population,
thus represents one of the most common brain disorders.
Epilepsy arises from diverse etiologies including genetic, struc-
tural, metabolic, or in other instances, the cause is unknown.
There is currently no medication available to effectively prevent
epilepsy by targeting the mechanisms underlying the enduring
predisposition to recurrent seizures, and nearly half of the patients
with epilepsy fail to respond to anticonvulsants that only alleviate
Abbreviations: ACTH, adrenocorticotrophic hormone; AMPAR, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BBB, blood–brain barrier;
CNS, central nervous system; COX-2, cyclooxygenase-2; CSF, cerebrospinal ﬂuid;
DAMPs, damage-associated molecular patterns; EEG, electroencephalography;
FDA, U.S. food and drug administration; GABA, gamma-aminobutyric acid;
GABA-BR, gamma-aminobutyric acid beta receptor; GLuR3, glutamate receptor
3; HMGB1, high mobility group box 1; ICAM-1, intracellular adhesion molecule-1;
IFN-γ, interferon-γ; IgG, immunoglobulin G; IL-1β, interleukin-1β; IL-1R/TLR,
interleukin-1 receptor/toll-like receptor; IL-6, interleukin-6; IVIG, intravenous
gammaglobulin; LPS, lipopolysaccharide; NMDA,N-methyl-D-aspartate; NMDAR,
N-methyl D-aspartate receptor; NR2B, NMDA receptor subtype 2B; PAMPs,
pathogen-associated molecular patterns; Smad, small mothers against decapenta-
plegic; TGF-β, transforming growth factor-β; TLE, temporal lobe epilepsy; TNF-α,
tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1; VGCC, N-
type voltage-gated calcium channel; VGKC LGI1, glycine receptor, voltage gated
potassium channel leucine-rich glioma-inactivated 1.
symptoms. Thus, there is a pressing need for the development
of effective disease-modifying therapies that treat the underlying
pathology. Such development can best be accomplished through
an in depth understanding of the disease mechanisms.
Until a decade ago, epilepsy research focused on alterations of
neuronal activities. Such neurocentric emphasis failed to address
questions that arose inmore complexmodels of epileptogenesis. A
cumulative body of knowledge has suggested that the pathogenesis
of epilepsy is associated with non-neuronal components, such as
the glial cells that exceedingly outnumber neurons, brain vascu-
lar cells, and more importantly leukocytes from the periphery.
Despite a long-held belief that the brain is an immunoprivi-
leged site due to the vascular blood–brain barrier (BBB) that
tightly regulates inﬁltration of blood constituents and the lack
of a lymphatic drainage, mounting evidence has supported the
critical role of immune responses in the initiation and mainte-
nance of epilepsy (Vezzani and Granata, 2005; Vezzani and Baram,
2007; Choi et al., 2009; Riazi et al., 2010). Ongoing brain inﬂam-
mation has the potential to lower seizure threshold, which in
turn may promote neuronal excitability through modiﬁcations
of neuronal channels, alterations of neurotransmitter uptake or
release, and regulation of BBB permeability (Viviani et al., 2007;
Wetherington et al., 2008; Friedman et al., 2009; Vezzani et al.,
2011a).
Both innate and adaptive immune responses can be primed
in the brain with the contribution of resident immune cells
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and mediators, as well as leukocytes inﬁltrating from the
periphery (Ransohoff et al., 2003; Banks and Erickson, 2010).
The innate arm of the response involves the activation of
the IL-1 receptor/toll-like receptor (IL-1R/TLR) signaling path-
ways through ligation of pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs),
activation of the cyclooxygenase-2 (COX-2) pathway, and initi-
ation of the transforming growth factor-β/small mothers against
decapentaplegic (TGF-β/Smad) signaling cascade. Inﬂammatory
mediators produced by the innate immune system remodel the
BBB by enhancing its permeability and upregulating leukocyte
adhesion molecules on the endothelium, which acts to attract
lymphocytes of the adaptive immune system leading to their
inﬁltration into the CNS.
This review focuses on the roles of immune responses in
the pathogenesis of epilepsy by summarizing the most recent
ﬁndings generated from human studies and animal models
that help delineate the contributions of brain inﬂammation in
epileptogenesis. We will evaluate the causal relationship between
inﬂammation and seizure activities and the positive feedback
loop they establish by revisiting the experimental evidence from
in vivo and in vitro models. Furthermore, we will provide
mechanistic insights into the immunological cascade that pre-
cedes the establishment of epilepsy and assess the inﬂuences of
immune mediators apart from the neurological aspect of seizure
induction. Finally, we will propose potential mechanisms that
underlie epileptogenesis and discuss development of therapies
targeting the key constituents and processes identiﬁed in these
mechanisms.
PRE-CLINICAL DATA UNDERSCORING THE RELEVANCE OF
IMMUNE RESPONSES IN EPILEPSY
Rodent models of epilepsy have provided ample evidence sup-
porting the role of immune responses in the precipitation of
epilepsy, modulation of seizure threshold, orchestration of seizure
recurrence, regulation of brain cell survival or attrition, and
rewiring of neuronal circuits that may lead to establishment
of hyperexcitable neuronal networks (Dube et al., 2005; Kulka-
rni and Dhir, 2009; Riazi et al., 2010; Vezzani et al., 2011a,b).
Adult and immature rats and mice are frequently used to elu-
cidate the role of various immunological pathways that are
potentially involved in seizure generation. Administration of
proinﬂammatory or anti-inﬂammatory agents to rats and mice
has been used to assess the inﬂuence of these immune medi-
ators on latency to onset, frequency, duration, and phenotype
of provoked seizures. Furthermore, the inﬂammatory path-
ways can be blocked pharmacologically in wildtype animals
or manipulated in transgenic mice to evaluate their role in
seizure severity (Kulkarni and Dhir, 2009; Maroso et al., 2010;
Vezzani et al., 2011a). Additionally, the availability of geneti-
cally modiﬁed mice with impaired or constitutively hyperactive
immunoregulatory pathways enables more detailed mechanis-
tic studies of inﬂammation-related epileptogenesis (Campbell
et al., 1993; Probert et al., 1997). Guinea pigs models, though
less common, have also been used to elucidate the contribution
of peripheral immune cells to seizure induction (Librizzi et al.,
2010).
RESIDENT IMMUNE MEDIATORS OF THE BRAIN
It has long been appreciated that chemically induced or electrically
stimulated prolonged seizures in rats and mice lead to induction
of robust immune responses in the seizure-laden brain (Minami
et al., 1991; Eriksson et al., 2000; De Simoni et al., 2000; Vezzani
et al., 2000; Turrin and Rivest, 2004; Voutsinos-Porche et al., 2004;
Gorter et al., 2006; Jung et al., 2006; Yoshikawa et al., 2006; Aronica
et al., 2007; Dhote et al., 2007; Lee et al., 2007; Kulkarni and Dhir,
2009; Holtman et al., 2010; Polascheck et al., 2010). Immunohis-
tochemical analyses performed on sections of affected brains have
revealed that various cell type, including microglia, astrocytes,
neurons, ependymal cells in the ventricles, and endothelial cells of
the BBB, were involved in the waves of inﬂammation associated
with seizure induction (Takao et al., 1990; Ban et al., 1991; Tur-
rin and Rivest, 2004; Chakravarty and Herkenham, 2005; Ravizza
and Vezzani, 2006). Activation of the IL-1R/TLR inﬂammatory
pathway was among the ﬁrst to be identiﬁed in these brain res-
ident immune cells. Constitutive expression of IL-1R and TLR
has been detected in the brain, though at a suboptimal level.
Upon stimulation, such as viral or bacterial infections, cellular
injuries, ischemia, and seizures, upregulation of these recep-
tors is readily detectable (Ericsson et al., 1995; Allan et al., 2005;
Peltier et al., 2010; Zurolo et al., 2011). Activation of TLRs, par-
ticularly TLR2 and TLR4, through systemic or cortical delivery
of lipopolysaccharide (LPS) to rats, results in rapid changes in
neuronal excitability, e.g., alteration in synaptic transmission and
regulation of long-term potentiation (Bellinger et al., 1993; Plata-
Salaman andFfrench-Mullen,1994; Schneider et al., 1998; Rodgers
et al., 2009). The excitatory effect of IL-1β has also been reported
to be associated with the reduction of gamma-aminobutyric acid
(GABA) inhibition and reduced outward current of voltage-gated
Ca2+ channels in the hippocampus (Zeise et al., 1997; Wang
et al., 2000; Viviani et al., 2007; Schafers and Sorkin, 2008). The
role of IL-1β in seizure sensitivity was further supported by
an in vitro system that demonstrated that N-methyl-D-aspartate
(NMDA)-mediated Ca2+ inﬂux is enhanced by activation of Src-
dependent NMDA receptor subtype 2B (NR2B) phosphorylation
(Viviani et al., 2003). In addition to PAMPs, DAMPs have been
recently shown to stimulate TLRs, especially TLR4, to exacerbate
seizures. The endogenous signals of DAMPs, such as high mobil-
ity group box 1 (HMGB1), can be released by stressed neurons
or activated microglia and astrocytes, suggesting that LPS may
have mimicked the endogenous DAMP pathway to cause seizure
(Maroso et al., 2010). Astrocytes can also enhance seizure induc-
tion through increased release of glutamate when the IL-1R/TLR
pathway is activated (Wetherington et al., 2008; Friedman et al.,
2009).
After the activation of the IL-1R/TLR pathway in the glial
population, upregulation of COX-2 and prostaglandins in neu-
rons often ensues (Yamagata et al., 1993; Rozovsky et al., 1994;
Yoshikawa et al., 2006; Kulkarni and Dhir, 2009). Inhibition of
COX-2 activation prior to seizure induction results in increased
mortality and exacerbated seizures behaviors in mice (Baik et al.,
1999; Toscano et al., 2008). In contrast, ablation of COX-2
production after seizure induction has been shown to be neuro-
protective and resulted in decreased production of inﬂammatory
cytokines by glia and prevented leakage of BBB in a conditional
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COX-2 knockout mouse strain (Serrano et al., 2011). However,
constitutive inhibition of COX-2 failed to prevent the recurrent
of unprovoked seizures (Holtman et al., 2010). Thus, it remains
unclear whether induction of COX-2 in neurons leads to enhanced
epileptogenesis.
After the induction of status epilepticus, serum albumin is
detected in the brain suggesting that in BBB failuremay contribute
to the development of epilepsy (van Vliet et al., 2007). Extravasa-
tion of albumin into the cerebral cortex as a result of compromised
BBB leads to activation of the TGF-β signaling pathway in astro-
cytes, and hence increases local inﬂammation. Such inﬂammatory
responses in the brain parenchyma would most likely induce
another wave of neuronal hyperactivation and attrition, which
leads to excretion of danger signals, such as DAMPs that would
further activate glia to boost inﬂammation. Thus, a positive feed-
back loop involves seizure, glia, neurons, and immune responses
in the brain.
INFILTRATING IMMUNE MEDIATORS OF THE BRAIN
It has long been appreciated that prolonged seizures lead to
upregulation of adhesion molecules on brain endothelial cells to
facilitate extravasation of circulating leukocytes. Expression of E-
selectin, P-selectin, intracellular adhesion molecule-1 (ICAM-1),
and vascular cell adhesion molecule-1 (VCAM-1) are increased
on the endothelial cells of the brain (Bell and Perry, 1995; Librizzi
et al., 2007). The ligands of these molecules, integrins andmucins,
are expressed by circulating leukocytes after seizure and facilitate
rolling and tethering of granulocytes and lymphocytes (Fabene
et al., 2008). Blockade of α4β1 integrins on leukocytes inhibits
inﬁltration of this cell population into the brain, and therapeutic
inhibition of α4 integrin activation prevents induction of seizure,
and even development of epilepsy (Fabene et al., 2008).
CLINICAL EVIDENCE OF THE INVOLVEMENT OF IMMUNE
RESPONSES IN EPILEPSY
ANTI-INFLAMMATORY THERAPIES THAT ARE EFFECTIVE AT TREATING
EPILEPSY
The efﬁcacy of anti-inﬂammatory medications, such as corti-
costeroids and adrenocorticotrophic hormone (ACTH), in the
treatment of some pediatric epilepsies that do not respond to
conventional anticonvulsants was one of the ﬁrst lines of clinical
evidence that epilepsy has an immune inﬂammatory compo-
nent (Hrachovy et al., 1983; Mackay et al., 2004). It has been
shown that ACTH had superior efﬁcacy in the cessation of
spasms, improved developmental prognosis, and normalization
of electroencephalography (EEG; Snead et al., 1983; Baram et al.,
1996; Kivity et al., 2004). In the treatment of refractory epileptic
encephalopathies, such as West syndrome, Ohtahara syndrome,
Dravet syndrome, Lennox-Gastaut syndrome, Landau-Kleffner
syndrome, epilepsywith continuous spikewaves during slow-wave
sleep and drug-resistant myoclonic atonic epilepsy, a signiﬁcant
proportion of ACTH- and steroid-treated pediatric patients were
reported to be seizure-free for an extended period of time, albeit
relapsed over time (Yamatogi et al., 1979; Snead et al., 1983; Donat,
1992; Engel, 2001).
In addition to, the corticosteroid therapies, intravenous gam-
maglobulin (IVIG) has been considered as another potential
treatment for refractory epilepsy (Eibl and Wedgwood, 1989).
The mechanisms of IVIG induced immunomodulation include
suppression of proinﬂammatory cytokines, interference with
antibody-dependent cytotoxicity through Fc receptor blockade,
dampening innate immune responses by inhibition of phagocyto-
sis by antigen presenting cells and complement uptake, as well as
neutralizationof autoantibodies. IgGhas been reported to be read-
ily detected in the cerebrospinal ﬂuid (CSF) after a single dose of
IVIG in neuromuscular disorders, suggesting that IVIG is capa-
ble of crossing the BBB (Cutler et al., 1970; Sekul et al., 1994;
Dalakas, 1998). Furthermore, the compromised BBB in many
types of epilepsy might further facilitate delivery of IVIG into
the brain to exert local immuno- and neuro-modulating effects
for seizure alleviation. In a double-blind clinical trial, seven doses
of IVIG was administered over a time period of 6 weeks, andmore
than 50% of the patients in the treatment group had a signiﬁ-
cant reduction of seizures (van Rijckevorsel-Harmant et al., 1994).
Similar effects of seizure reduction and temporaryEEGnormaliza-
tion were observed in another trial using pediatric patients (Hart
et al., 1994). The use of IVIG in intractable epilepsy and status
epilepticus merits further investigation as consistent efﬁcacious
outcome has not been achieved and the dosing regimen remains
to be optimized.
Blockade of cell-adhesion molecules involved in lymphocyte
trafﬁcking has also shown promise in ameliorating seizure severity
in epilepsy. Natalizumab, an FDA approved humanized antibody
speciﬁc to a homing molecule (α4β1 integrin) that directs lym-
phocyte migration to inﬂamed tissues, including the brain, has
been shown to signiﬁcantly reduce generalized seizures and status
epilepticus in adult patients who also suffered from a autoimmune
demyelinating disease, multiple sclerosis (Ley et al., 2007; Sotgiu
et al., 2010; Fabene et al., 2013)
EPILEPTOGENIC TRIGGER WITH AN INTRINSIC INFLAMMATORY
NATURE
Febrile status epilepticus is intrinsically associated with immune
responses. Genetic susceptibility to inﬂammation, though not an
obligatory factor, has been suggested to lower the seizure thresh-
old, as nearly 30% of febrile seizure patients have such a family
history. In addition, mutations in the IL-1β gene segment predis-
pose patients to prolonged febrile convulsions (Millichap, 1959;
Virta et al., 2002; Kanemoto et al., 2003). An elevation in a number
of proinﬂammatory cytokines caused by neurotropic viral infec-
tions, for instance, human herpesvirus-6 and inﬂuenza viruses,
is also commonly associated with febrile seizures in infants and
young children (Hall et al., 1994; Chiu et al., 2001). Detection of
viral DNA is more frequent in the CSF of patients with repetitive
febrile seizures than in those patients with a single seizure (Kondo
et al., 1993). Increased levels of Th1 and Th2 cytokines, such as
interferon-γ (IFN-γ) and interleukin-6 (IL-6), have been reported
in inﬂuenza-infected patients who later developed febrile seizures,
when compared with the virally infected control subjects without
seizures (Chiu et al., 2001; Masuyama et al., 2002; Kawada et al.,
2003).
Rasmussen’s encephalitis, a prototypic childhood inﬂamma-
tory epilepsy, is a progressive immune-mediated brain disor-
der characterized by focal recurrent seizures (epilepsia partialis
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continua), unilateral hemispheric atrophy, progressive neurolog-
ical dysfunction and intractable epilepsy. Rasmussen encephalitis
is associated with T-cell activation and production of proinﬂam-
matory cytokines by activated glia. Effector CD8+ cytotoxic T
lymphocytes are proposed to induce astrocytic andneuronal apop-
tosis and degeneration, one of the hallmarks of Rasmussen’s
encephalitis (Bauer et al., 2007). An autoantigen, a glutamate
receptor, GluR3, has been detected in this disease. Removal
of the GluR3-speciﬁc antibody from the circulation has been
shown to ameliorate seizure severity, promote neurological func-
tions, and improve the disease prognosis. However, anti-GluR3
antibody is not present in most cases and immune modulation
including IVIG, steroid and plasmapheresis has limited efﬁcacy
(Rogers et al., 1994; He et al., 1998; Mantegazza et al., 2002; Wat-
son et al., 2004). Hemispherectomy remains the only “cure” of
disease progression.
In recent years, an increasing number of autoantibodies
have been detected in serum and CSF of patients with new
onset drug-resistant focal epilepsy. A deﬁnitive diagnosis and
therapy have thus been possible for cases that would have
been previously categorized as viral or idiopathic encephali-
tis/epilepsies. The California Encephalitis Project found that
the frequency of autoimmune encephalitis was greater than
any single viral etiology. Anti-N-methyl D-aspartate receptor
(NMDAR) encephalitis was, in fact, the most frequent cause of
immune-mediated encephalitis (Armangue et al., 2013). Autoim-
mune/inﬂammatory epilepsy is deﬁned as immunologicallymedi-
ated disorder where recurrent seizures are prominent feature and
immune etiology is suggested by detection of neuronal antibod-
ies, presence of inﬂammatory changes in CSF or upon MRI,
or immunotherapy-responsive symptoms and exclusion of other
etiologies. Autoimmune/inﬂammatory epilepsies include lim-
bic encephalitis (both paraneoplastic and non-paraneoplastic),
non-limbic encephalitis complicated by seizures, seizures in the
context of autoimmune disease, and neural antibody-mediated
CNS disorders where seizures are a signiﬁcant feature. Disease
causing autoantibodies have been detected against the follow-
ing speciﬁc neuronal surface proteins: NMDAR, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR),
γ-aminobutyric acid beta receptor (GABA-BR), glycine receptor,
voltage gated potassium channel leucine-rich glioma-inactivated
1 (VGKC LGI1),VGKC CASPR2 and P/Q or N-type voltage-gated
calcium channel (VGCC; Armangue et al., 2012).
The paraneoplastic type is thought to be caused by self-reactive
T lymphocytes, although antibodies speciﬁc for intracellular com-
ponents are often detectable (Dalmau and Rosenfeld, 2008).
The non-paraneoplastic category is consistently associated with
seizure-inducing autoantibodies that target extracellular mem-
brane components, including voltage-gated channels, NMDAR,
and glutamic acid decarboxylase (Bien et al., 2007; Dalmau et al.,
2008; Vincent and Bien, 2008; Dalmau, 2009; Vincent et al.,
2010). These antibodies cause seizures by modifying neuronal
excitability, which has been recapitulated in an in vitro model
by measuring hippocampal neuronal ﬁring frequency follow-
ing autoantibody treatment (Vianello et al., 2008). Due to its
autoimmunenature, limbic encephalitis responds to immunother-
apies, including steroids and IVIG through the mechanisms
of dampening T-cell immunity and neutralizing autoantibod-
ies (Dalmau, 2009). Another type of autoimmune epilepsy
that also responds to corticosteroid treatments is Hashimoto’s
encephalopathy. Self-reactive antibodies in this syndrome tar-
get thyroid peroxidase or thyroglobulin, and are very potent
in seizure induction (Castillo et al., 2006; Watemberg et al.,
2006).
DETECTION OF IMMUNE MEDIATORS IN THE BRAIN OF PATIENTS WITH
EPILEPSY
Leukocyte accumulation in the perivascular space, and occasion-
ally the parenchyma, of epileptic brain in pediatric as well as
adult patients provide another line of evidence that immune
cell invasion of the central nervous system (CNS) may be crit-
ical in orchestrating epileptogenesis. CD3+ lymphocytes and
myeloid-derivedmacrophages have beendetected in resectedbrain
samples of patients diagnosed with temporal lobe epilepsy (TLE;
Ravizza et al., 2008). A subset of CD3+ cells, cytotoxic CD8+ T
lymphocytes, has also been found in the gray and white mat-
ter of epileptic patients with tuberous sclerosis complex (Boer
et al., 2008). Brain-inﬁltrating granulocytes and T cells have
been additionally demonstrated in epilepsy of diverse etiologies
(Fabene et al., 2008). In line with the above ﬁndings, our lab-
oratory and others have detected a myriad of immune-related
genes that are upregulated in surgical specimens from patients
with intractable TLE using a global survey of changes in gene
expression. These immune-related genes include chemokines,
complement components,metalloproteinases and their inhibitors,
adhesion molecules, immune receptors such as MHC molecules
and Fc receptors, and heat shock proteins (Aronica and Gorter,
2007; van Gassen et al., 2008).
PROPOSED IMMUNE MECHANISMS OF EPILEPTOGENESIS
Understanding the immune mechanisms underlying epileptoge-
nesis provide insights into the development of more effective
target-speciﬁc immunotherapies rather than general treatments
that non-speciﬁcally suppress or regulate the immune responses.
Ample experimental and clinical evidence has suggested that
inﬂammation in the brain is likely to predispose, precipitate, and
perpetuate epileptogenesis, however, protective immune responses
that promote neuronal repair and restores homeostasis also exist in
epilepsy as well as other immune-mediated neurological disorders,
such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s
neurodegeneration. Thus, whether the immune response detected
during the initiation and development of epilepsy is always dele-
terious to the survival of brain cells or perhaps may also mediate
neuroprotective functions merits further in-depth investigation.
The current dominant view of immune-mediated epileptogen-
esis entails contributions from both brain-resident cells capable of
innate immune responses as well as peripherally derived inﬁltrat-
ing innate and adaptive immune effector cells. The pathological
triggering events that are initiated in the brain or the periphery
for a variety of reasons, such as simple febrile seizures, trauma,
stroke or infection, may lead to an inﬂammatory cascade. Acti-
vation of glia, neurons, and endothelial cells that constitute the
BBB most likely result in the release proinﬂammatory cytokines,
such as IL-1β and TNF-α, and danger signals, such as HMGB1.
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FIGURE 1 | Proposed immune mechanisms in epileptogenesis. The
relationship between the immune system and the development of epilepsy
is non-linear, but rather better represented as an amplifying feedback loop.
The immune response predisposes, precipitates and perpetuates
epileptogenesis through activation of resident brain cells (glia and neurons)
and facilitation of peripheral leukocyte inﬁltration. These immune mediators
release proinﬂammatory cytokines and chemokines into the brain
parenchyma and the blood, thereby activating downstream signaling
cascades and compromising blood–brain barrier, which leads to
pathophysiological outcomes, reoccurrence of seizures, and ultimately the
development of epilepsy.
These factors activate cognate pathways in neurons to cause an
intracellular calcium ion surge, which results in modiﬁcation
of voltage-dependent ion channels. Dysregulated ion channels
directly enhance the neuronal hyperexcitability and reduce seizure
threshold. In addition, proinﬂammatory cytokines also stimu-
late chronic release of neuroexcitatory transmitters, inhibit uptake
of these neurotransmitters by the glial population, and restrict
the recycling of GABA receptors (Hu et al., 2000; Bezzi et al.,
2001; Stellwagen et al., 2005; Ferguson et al., 2008). COX-2 and
prostaglandin can also be involved in such a process that remodels
the neuronal network by mobilizing intracellular calcium storage
and an increase in cAMP production.
The inﬂammatory milieu and the neuronal hypersynochro-
nization in the CNS are often accompanied by BBB leakage, which
introduces tightly regulated blood components, such as albu-
min and potassium ion, into the brain (Seiffert et al., 2004; Oby
and Janigro, 2006; Aronica et al., 2007; Ivens et al., 2007; Shlos-
berg et al., 2010). Increased leukocyte adhesion to the endothelial
cells further modiﬁes the BBB through cytoskeletal organization,
which results in enhanced leukocyte inﬁltration into the brain
(Greenwood et al., 2002). Upon entering the brain, activated
peripheral immune cells are capable of generating free radicals,
releasing additional chemokines, cytokines, nitric oxide, and cyto-
toxic enzymes to establish a self-amplifying cascade to further
precipitate epileptogenesis.
CONCLUSION
Animal models and clinical evidence highlight the involvement
of CNS resident and peripherally derived inﬁltrating immune
mediators in seizure induction and epilepsy development (Vez-
zani et al., 2011a). Robust immune responses in the brain decrease
seizure threshold, enhance neuronal excitability, induce BBB fail-
ure, promote synaptic reorganization, and regulate epileptogenesis
(Figure 1). Despite the appreciation of the critical role of immu-
nity in epileptogenesis and the advancements made in the recent
years in understanding the immunological mechanisms underly-
ing epilepsy, novel diagnostic measures and effective therapeutic
treatments that targets immunological pathways are still lacking.
In addition to, the glial populations and neurons, which are
the major brain-resident immune mediators in epilepsy, periph-
eral leukocytes that inﬁltrate the brain are also being investigated
for their contribution to epileptogenesis as a result of a com-
promised BBB, for instance, macrophages, monocytes, dendritic
cells, αβ T lymphocytes, γδ T lymphocytes, and regulatory cells.
Several inﬂammatory signaling pathways have been identiﬁed
which initiate immune responses involving the aforementioned
immune mediators. Activation of the IL-1R/TLR pathway may
be due to brain injury or infection, but could also be caused by
DAMPs, such as HMGB1. Furthermore, COX-2 induced produc-
tion of prostaglandins is capable of triggering brain inﬂammation
(Fabene et al., 2008; Serrano et al., 2011). Therefore, pharmaco-
logical blockade of these signaling pathways and inhibitors that
antagonizing the main immune mediators have the potential of
becoming the next generation of effective anti-epileptic treatment.
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